Compare AbCellera Biologics Inc (ABCL) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs PepsiCo, Inc. — how do they compare? AbCellera Biologics Inc trades at $9.5 (market cap $2.99B), while PepsiCo, Inc. trades at $136.85 (market cap $188.91B). The key difference: PepsiCo, Inc. is far larger — about 63.2× AbCellera Biologics Inc's market cap, and PepsiCo, Inc. pays a 4.28% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | PEP | |
|---|---|---|
Market Cap | $2.99B | $188.91B |
Sector | Health | Consumer Staples |
52-Week High | $9.76 | $170.44 |
52-Week Low | $2.78 | $134.95 |
Enterprise Value | $2.58B | $231.41B |
Dividend Yield | — | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
PepsiCo (PEP) trades at $137.69, down 0.95% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company maintains strong fundamentals with $93.93B revenue in 2025, 10.78% net margin, and consistent dividend payments. Recent news highlights price adjustments for snack products and sponsorship withdrawals, while analysts project 15% upside to the $158.79 consensus target.
PepsiCo presents a mixed outlook with solid fundamentals and dividend yield offset by near-term price pressure and competitive challenges. The stock offers value at current levels for income investors, though execution risks in North America and consumer pricing sensitivity require monitoring. Wall Street maintains cautious optimism with 64% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
